Botulinum toxin type A induces apoptosis of human hypertrophic scar fibroblasts

doi:10.3969/j.issn.2095-4344.2013.24.009

Abstract

Abstract:

BACKGROUND: Botulinum toxin type A can be used to treat human hypertrophic scar clinically and inhibit the proliferation of human hypertrophic scar fibroblasts in vitro.
OBJECTIVE: To investigate the effect of botulinum toxin type A on the proliferation and apoptosis of human hypertrophic scar fibroblasts.
METHODS: Human hypertrophic scar fibroblasts were isolated and cultured using digestion method. The cells were treated with botulinum type A at different concentrations. After 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide dyeing, the cell solutions were detected with enzyme-linked immunosorbent detector at 570 nm. The inhibitory rate was calculated. The cultured cells were stained with hoechst 33342 and PI. The apoptotic cells were observed under fluorescence microscopy and the apoptotic rate was calculated.
RESULTS AND CONCLUSION: The hypertrophic scar fibroblasts represented the spindle-like character with uniform composition and strong proliferation. After treated with botulinum toxin type A, the cells grew slowly, the cell amount reduced and the arrangement of the cells was scattered. The absorbance after 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide dyeing decreased. There was a statistically significant difference compared with the control group (P < 0.05). The half inhibitory rate was 0.4 IU/L. After hoechst 33342 and PI dyeing, the nuclei became blue and showed a smooth round or oval appearance. After treated with botulinum toxin type A, the nuclei were condensed with uneven dyeing. Some of the nuclei were fragmented and apoptotic bodies appeared. The apoptotic rate was increased with increasing concentrations of botulinum toxin type A. There was a statistically significant difference between the control group and the treated group (P < 0.05). The half apoptotic rate was 0.4 IU/L. These findings indicate that botulinum toxin type A can cause apoptosis of the human hypertrophic scar fibroblasts, thus inhibiting the proliferation of the cells.

Key words: tissue construction, skin tissue construction, botulinum toxin type A, hypertrophic scar, fibroblasts, nuclei, cell culture, apoptosis, proliferation, skin, scar, burn

CLC Number:

R318

Li Wei-hua, Gao Yu-wei, Li De-shui, Xing Yu-xi. Botulinum toxin type A induces apoptosis of human hypertrophic scar fibroblasts[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(24): 4429-4435.

Figures/Tables 3

References

[1] Wu BJ, Wu JM, Lin ZH, et al. Zhonghua Shaoshang Zazhi. 2006;22(06):469-470.吴包金,吴建明,林子豪,等.增生性瘢痕退行性变过程中的细胞凋亡和相关基因表达[J].中华烧伤杂志,2006,22(06):469-470.http://www.cnki.com.cn/Article/CJFDTotal-ZHSA200606028.htm

[2] Wang L, Tai NZ, Fan ZH, et al. ZHonghua Zhengxing Waike Zazhi. 2009;4:284-287.王琳,邰宁正,范志宏, 等. A型肉毒毒素对兔耳增生性瘢痕组织中P物质、β1转移生长因子、α平滑肌肌动蛋白的影响[J].中华医学美学美容杂志,2009,6:410-413.http://www.cqvip.com/QK/71135X/201107/32577654.html

[3] Wang L, Tai NZ, Fu MG, et al. Zhonghua Zhengxing Waike Zazhi. 2009;25(3):222-223.王琳,邰宁正,傅敏刚,等.A型肉毒毒素注射治疗瘢痕疙瘩患者的顽固性痛痒[J].中华整形外科杂志,2009,25(3): 222-223.http://www.cqvip.com/QK/71135X/201107/30537397.html

[4] Zhao BC, Qian L. Hunana Yike Daxue Xuebao. 2000;25(1): 73-76.赵柏程,钱利.增生性瘢痕和瘢痕疙瘩组织中细胞凋亡与增殖的研究[J]．湖南医科大学学报,2000,25(1):73-76.http://www.cnki.com.cn/Article/CJFDTotal-HNYD200001027.htm

[5] Yu B, Chen ML, Liu WG, et al. Zhonghua Yixue Meixue Meirong Zazhi. 2008;14(2):95-101.于波,陈敏亮,刘文阁,等.A型肉毒毒素预防与治疗早期增生性瘢痕的临床研究[J].中华医学美学美容杂志,2008,14(2):95-101.http://med.wanfangdata.com.cn/News/Article/1/1826.aspx

[6] Gauqlitz GG, Bureik D,Dombrowski Y,et al. Botulinum toxin a for the treatment of keloids. Skin Pharmacol Physiol. 2012;25 (6):318-319.http://www.ncbi.nlm.nih.gov/pubmed/22948093

[7] Li WH, Li DS, Gao YW, et al. Zhonguo Zuzhi Gongcheng Yanjiu. 2012;16(20):3667-3670.李卫华,李德水,高玉伟,等.A型肉毒毒素可抑制人增生性瘢痕成纤维细胞增殖和胶原蛋白合成[J].中国组织工程研究,2012,16 (20): 3667-3670.http://www.cnki.com.cn/Article/CJFDTotal-XDKF201220022.htm

[8] Haubner F, Ohmann E, Müller-Vogt U, et al. Effects of botulinum toxin a on cytokine synthesis in a cell culture model of cutaneous scarring. Arch Facial Plast Surg. 2012;14(2):122-126.http://www.ncbi.nlm.nih.gov/pubmed/22006235

[9] Hevia O.Retrospective review of 500 patients treated with abobotulinumtoxin A.J Drugs Dermatol. 2010;9(9):1081-1084.http://www.ncbi.nlm.nih.gov/pubmed/20865838

[10] Levy NS, Lowenthal DT. Application of botulinum toxin to clincal therapy: advances and cautions. Am J Ther. 2012; 19(4): 281-286.http://www.ncbi.nlm.nih.gov/pubmed/22481607

[11] Dresslor D. Parmacology of botulinum toxin drugs. HNO.2012; 60(6):496-504.http://www.ncbi.nlm.nih.gov/pubmed/23054049

[12] Cable MM. On the front lines: What’s new in botox and facial fillers. Mo Med.2010;36:2121-2134.http://www.ncbi.nlm.nih.gov/pubmed/21319685

[13] Beer Kr. Combined treatment for skin rejuvenation and soft-tissue augmentation of the aging face. J Drugs Dermatol. 2011;10(2):125-132.http://www.ncbi.nlm.nih.gov/pubmed/21283916

[14] Goldman A, Wollina U. Facial rejuvenation for middle-aged women: a combined approach with minimally invasive procedures. Clin Interv Aging.2010;23(5):293-299.http://www.ncbi.nlm.nih.gov/pubmed/20924438

[15] Raspaldo H, Baspeyras M,Bellity P,et al.Upper- and mid-face anti-aging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus—part 1. J Cosmet Dermatol.2011;10(1):36-50.http://www.ncbi.nlm.nih.gov/pubmed/21332914

[16] Sepehr A,Chauhan N,AlexanderAJ,et al.Botulinum toxin type a for facial rejuvenation: treatment evolution and patient satisfaction.Aesthetic Plast Surg.2010;34(5):583-586.http://www.ncbi.nlm.nih.gov/pubmed/20383497

[17] Andrade NN, Deshpande GS. Use of botulinum toxin (botox) in the management of masseter muscle hypertrophy: a simplified technique. Plast Reconstr Surg.2011;128(1):24-26.http://www.ncbi.nlm.nih.gov/pubmed/21701301

[18] Pary A,Pary K.Masseteric hypertrophy: considerations regarding treatment planning decisions and introduction of a novel surgical technique. J Oral Maxillafac Surg.2011;69(3): 944-949.http://www.ncbi.nlm.nih.gov/pubmed/21195532

[19] Jaspers GW, Pijpe J, Jansma J.The use of botulinum toxin type A in cosmetic facial procedures. Int Oral Maxillofac Surg. 2011; 40(2):127-133.http://www.ncbi.nlm.nih.gov/pubmed/20965695

[20] Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrphy of the masseter muscle. Plast Reconstr Surg.2010;125(6):1693-1705.http://www.ncbi.nlm.nih.gov/pubmed/22842446

[21] Lee BJ,Jeong JH,Wang SG,et al.Effect of botulinum toxin type a on a rat surgical wound model.Clin Exp Otorhinolaryngol. 2009; 2(1):20-27.http://www.ncbi.nlm.nih.gov/pubmed/19434287

[22] Venus MR.Use of botulinum toxin type A to prevent widening of facial scars.Plast Reconstr Surg. 2007;19(1):423-424.http://www.ncbi.nlm.nih.gov/pubmed/16651948

[23] Gassner HG,Brissett AE,Otley CC,et al.Botulinum toxin to improve facial wound healing:A prospective,blinded, placebo-controlled study. Mayo Clin Proc.2006;81(8): 1023-1028.http://www.ncbi.nlm.nih.gov/pubmed/16901024

[24] Wang L, Tai NZ, Fan ZH. Zhonghua Zhengxing Waike Zazhi. 2009;25(1):50-53. 王琳,邰宁正,范志宏.肉毒毒素A对大鼠皮肤及创面组织中SP、CGRP、TGF-β1和α-SMA的影响[J].中华整形外科杂志, 2009, 25(1):50-53.http://www.cqvip.com/QK/96147A/200901/29450569.html

[25] Xiao Z, Zhang F, Lin W, et al. Effect of botulinum toxin type A on transforming growth factor beta 1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesthetic Plast Surg. 2010;34(4):424-427.http://www.ncbi.nlm.nih.gov/pubmed/19802513

[26] Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-β family in wound healing, burns and scarring: a review. Int J Burns Trauma. 2012;2(1):18-28.http://www.ncbi.nlm.nih.gov/pubmed/22928164

[27] Huang C, Akaishi S, Oqawa R. Mechanosignaling pathways in cutaneous scarring. Arch Dermatol Res.2012;304(8): 589-597.http://www.ncbi.nlm.nih.gov/pubmed/22886298

[28] Abe M, Yokoyama Y, Ishikawa O. A possible mechanism of basic fibroblast growth factor-promoted scarless wound healing: the induction of myofibroblast apoptosis. Eur J Dermatol. 2012;22(1):46-53.http://www.ncbi.nlm.nih.gov/pubmed/22370167

[29] Hounardoust D, Varkey M, Marcoux Y, et al. Reduced decorin, fibromodulin, and transforming growth factor-β3 in deep dermis leads to hypertrophic scarring. J Burn Care Res. 2012; 33(2):218-227.http://www.ncbi.nlm.nih.gov/pubmed/22079916

[30] Liu J, Wang Y, Pan Q, et al. Wnt/β-catenin pathway forms a negative feedback loop during TGF-β1 induced human normal skin fibroblast-to-myofibroblast transition. J Dermatol Sci. 2012;65(1):38-49.http://www.ncbi.nlm.nih.gov/pubmed/22041457

[31] Moon H , Yong H, Lee AR. Optimum scratch assay condition to evaluate connective tissue growth factor expression for anti-scar therapy. Arch Pharm Res. 2012;35(2):383-388.http://www.ncbi.nlm.nih.gov/pubmed/22370794

[32] Guo F, Cater DE, Leask A. Mechanical tension increases CCN2/CTGF expression and proliferation in gingival fibroblasts via a TGFβ-dependent mechanism. Plos One. 2011;6(5):e19756.http://www.ncbi.nlm.nih.gov/pubmed/21611193

[33] Tao L, Liu J, Li Z, et al. Role of the JAK-STAT pathway in proliferation and differentiation of human hypertrophic scar fibroblasts induced by connective tissue growth factor. Mol Med Report. 2010;3(6):941-945.http://www.ncbi.nlm.nih.gov/pubmed/21472337

[34] Zhibo X,Miaobo Z.Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. J Plast Reconstr Aesthetic Surg.2008;61(9):1128-1129.http://www.ncbi.nlm.nih.gov/pubmed/18555763

[35] Chen W, Fu XB, Zhou G, et al. Zhonghua Shiyong Waike Zazhi. 2004;21(9):1111-1113.陈伟,付小兵,周岗,等. 增生性瘢痕内3种成纤维细胞生长因子及其受体基因的表达[J]. 中华实验外科杂志,2004,21(9): 1111-1113.http://www.cnki.com.cn/Article/CJFDTotal-ZHSY200409040.htm

[36] Jiang ZY, Fu XB, Sheng ZY, et al. Zhonghua Waike Zazhi. 2006,44(07):496-498.姜笃银,付小兵,盛志勇.瘢痕组织愈合中成纤维细胞凋亡抗性及其临床意义[J].中华外科杂志,2006,44(07):496-498.http://www.cnki.com.cn/Article/CJFDTotal-ZHWK200607017.htm